Literature DB >> 23459937

The differential effects of wild-type and mutated K-Ras on MST2 signaling are determined by K-Ras activation kinetics.

David Romano1, Helene Maccario, Carolanne Doherty, Niall P Quinn, Walter Kolch, David Matallanas.   

Abstract

K-Ras is frequently mutated in human cancers. Mutant (mt) K-Ras can stimulate both oncogenic transformation and apoptosis through activation of extracellular signal-regulated kinase (ERK) and AKT pathways and the MST2 pathway, respectively. The biological outcome is determined by the balance and cross talk between these pathways. In colorectal cancer (CRC), a K-Ras mutation is negatively correlated with MST2 expression, as mt K-Ras can induce apoptosis by activating the MST2 pathway. However, wild-type (wt) K-Ras can prevent the activation of the MST2 pathway upon growth factor stimulation and enable transformation by mt K-Ras in CRC cells that express MST2. Here we have investigated the mechanism by which wt and mt K-Ras differentially regulate the MST2 pathway and MST2-dependent apoptosis. The ability of K-Ras to activate MST2 and MST2-dependent apoptosis is determined by the differential activation kinetics of mt K-Ras and wt K-Ras. Chronic activation of K-Ras by mutation or overexpression of Ras exchange factors results in the activation of MST2 and LATS1, increased MST2-LATS1 complex formation, and apoptosis. In contrast, transient K-Ras activation upon epidermal growth factor (EGF) stimulation prevents the formation of the MST2-LATS1 complex in an AKT-dependent manner. Our data suggest that the close relationship between Ras prosurvival and proapoptotic signaling is coordinated via the differential regulation of the MST2-LATS1 interaction by transient and chronic stimuli.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23459937      PMCID: PMC3624182          DOI: 10.1128/MCB.01414-12

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  44 in total

1.  Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases.

Authors:  Joseph Avruch; Maria Praskova; Sara Ortiz-Vega; Matthew Liu; Xian-Feng Zhang
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

2.  Wild-type NRas and KRas perform distinct functions during transformation.

Authors:  Poppy P Fotiadou; Chiaki Takahashi; Hasan N Rajabi; Mark E Ewen
Journal:  Mol Cell Biol       Date:  2007-07-16       Impact factor: 4.272

3.  Identification of Nore1 as a potential Ras effector.

Authors:  D Vavvas; X Li; J Avruch; X F Zhang
Journal:  J Biol Chem       Date:  1998-03-06       Impact factor: 5.157

4.  RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network.

Authors:  Cai Guo; Stella Tommasi; Limin Liu; Jiing-Kuan Yee; Reinhard Dammann; Gerd P Pfeifer
Journal:  Curr Biol       Date:  2007-03-22       Impact factor: 10.834

5.  Cloning and characterization of a member of the MST subfamily of Ste20-like kinases.

Authors:  C L Creasy; J Chernoff
Journal:  Gene       Date:  1995-12-29       Impact factor: 3.688

6.  Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.

Authors:  David Matallanas; David Romano; Fahd Al-Mulla; Eric O'Neill; Waleed Al-Ali; Piero Crespo; Brendan Doyle; Colin Nixon; Owen Sansom; Matthias Drosten; Mariano Barbacid; Walter Kolch
Journal:  Mol Cell       Date:  2011-12-23       Impact factor: 17.970

7.  The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage.

Authors:  Sabrina Strano; Olimpia Monti; Natalia Pediconi; Alessia Baccarini; Giulia Fontemaggi; Eleonora Lapi; Fiamma Mantovani; Alexander Damalas; Gennaro Citro; Ada Sacchi; Giannino Del Sal; Massimo Levrero; Giovanni Blandino
Journal:  Mol Cell       Date:  2005-05-13       Impact factor: 17.970

Review 8.  The RASSF1A tumor suppressor.

Authors:  Howard Donninger; Michele D Vos; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2007-09-15       Impact factor: 5.285

9.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

Authors:  S Shirasawa; M Furuse; N Yokoyama; T Sasazuki
Journal:  Science       Date:  1993-04-02       Impact factor: 47.728

10.  Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor.

Authors:  M Hamilton; A Wolfman
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

View more
  15 in total

1.  RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis.

Authors:  M Lee Schmidt; Katharine R Hobbing; Howard Donninger; Geoffrey J Clark
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

2.  Characterisation of HRas local signal transduction networks using engineered site-specific exchange factors.

Authors:  Ana Herrero; Mariana Reis-Cardoso; Iñaki Jiménez-Gómez; Carolanne Doherty; Lorena Agudo-Ibañez; Adán Pinto; Fernando Calvo; Walter Kolch; Piero Crespo; David Matallanas
Journal:  Small GTPases       Date:  2018-01-15

Review 3.  Mitochondrial determinants of cancer health disparities.

Authors:  Aaheli Roy Choudhury; Keshav K Singh
Journal:  Semin Cancer Biol       Date:  2017-05-06       Impact factor: 15.707

4.  H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization.

Authors:  Sonali J Rawat; Daniela Araiza-Olivera; Luis E Arias-Romero; Olga Villamar-Cruz; Tatiana Y Prudnikova; Heinrich Roder; Jonathan Chernoff
Journal:  Curr Biol       Date:  2016-05-26       Impact factor: 10.834

5.  Rare codons capacitate Kras-driven de novo tumorigenesis.

Authors:  Nicole L K Pershing; Benjamin L Lampson; Jason A Belsky; Erin Kaltenbrun; David M MacAlpine; Christopher M Counter
Journal:  J Clin Invest       Date:  2014-12-01       Impact factor: 14.808

Review 6.  Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.

Authors:  Chih-Chieh Yu; Wanglong Qiu; Caroline S Juang; Mahesh M Mansukhani; Balazs Halmos; Gloria H Su
Journal:  Cancer Lett       Date:  2016-10-08       Impact factor: 8.679

Review 7.  Hras helps hippo heterodimerize to evade tumor suppression.

Authors:  Daniela Araiza-Olivera; Jonathan Chernoff
Journal:  Small GTPases       Date:  2016-09-20

Review 8.  Racial disparity in metabolic regulation of cancer.

Authors:  Kuldeep S Attri; Divya Murthy; Pankaj K Singh
Journal:  Front Biosci (Landmark Ed)       Date:  2017-03-01

Review 9.  Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?

Authors:  Stephanie McKenna; Lucía García-Gutiérrez
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

10.  Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling.

Authors:  Alexander Hergovich
Journal:  Cell Biosci       Date:  2013-08-28       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.